13 / 48
BIBLIOGRAFÍA
The Macular Photocoagulation Study Group. Laser
1.
Photocoagulation of subfoveal neovascular lesions
in age-related macular degeneration: results of a
randomized clinical trial. Arch Ophthalmol. 1991;
109: 1220-1231.
The Macular Photocoagulation Study Group.
2.
Laser Photocoagulation for juxtafoveal choroidal
neovascularisation: five-year results from randomized
clinical trials. Arch Ophthalmol. 1994; 112: 500-
509.
Macular Photocoagulation Study Group. Laser
3.
photocoagulation of subfoveal neovascular lesions
of age-related macular degeneration (Updated
findings from two clinical trials). Arch Ophthalmol.
1993;111:1200–1209
Treatment of Age-Related Macular Degeneration
4.
with Photodynamic Therapy (TAP) Study Group.
Photodynamic therapy for subfoveal choroidal
neovascularization in age-relatedmacular degeneration
with verteporfin (Two-year results of 2 randomized
clinical trials—TAP report 2). Arch Ophthalmol.
2001;119:198–207.
Photodynamic therapy of subfoveal choroidal
5.
neovascularization in age-related macular
degeneration with verteporfin: One year results
of 2 randomized clinical trials. TAP Report 1. Arch
Ophthalmol. 1999; 117: 1329-1345.
Gragoudas ES, Adamis AP, Cunningham ET, et
6.
al.VEGF Inhibition Study in Ocular Neovascularization
Clinical Trial Group Pegaptanib for neovascular
age-related macular degeneration. N Engl J Med.
2004;351:2805–2816.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab
7.
for neovascular age-related macular degeneration.
N Engl J Med 2006; 355: 1419-31.
Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab:
8.
phase III clinical trial results. Ophthalmol Clin North
Am. 2006;19:361–372.
Boyer DS, Antoszyk AN, Awh CC, et al.Subgroup
9.
analysis of the MARINA study of ranibizumab in
neovascular age-related macular degeneration.
Ophthalmology.
2007;114:246–252
.
Brown DM, Kaiser PK, Michels M, et al.Ranibizumab
10.
versus ver tepor fin for neovascular age -
related macular degeneration. N Engl J Med.
2006;355:1432–1444.
Brown DM. Phase IIIb, multicenter, randomized,
11.
double-masked, sham injection-controlled study of
the efficacy and safety of ranibizumab in subjects
with subfoveal choroidal neovascularization with or
without classic CNV secondary to age-related macular
degeneration (PIER) trial. Program and abstracts of
the Retinal Physician 2006 Symposium; May 31-June
3, 2006; Atlantis, Paradise Island, Bahamas.
Regillo CD, Brown DM, Abraham P, et al. Randomized,
12.
double-masked, sham-controlled trial of ranibizumab
for neovascular age-related macular degeneration:
PIER Study Year 1. Am J Ophthalmol. In press.
Rosenfeld PJ, Fung AE, Lalwani GA, Michels S,
13.
Venkatraman AS, Puliafito CA. Visual acuity outcomes
following a variable-dosing regimen for ranibizumab
(Lucentis) in neovascular AMD: the PrONTO Study.
Program and abstracts of the Association for Research
in Vision and Ophthalmology; April 30-May 4, 2006;
Fort Lauderdale, Florida. Abstract 2958.
Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical
14.
coherence tomography-guided, variable dosing
regimen with intravitreal ranibizumab (Lucentis)
for neovascular age-related macular degeneration.
Am J Ophthalmology.
2007;143:566-583
.
111
Anti VEGF en degeneración macular relacionada a la edad